Much noticed, much cited

advanceCOR is a company with strong research capabilities. Our scientists regularly publish their results in renowned scientific journals.


Zhongmin Li ,Goetz Muench,Silvia Goebel,Kerstin Uhland,Clara Wenhart,Andreas Reimann. Flow chamber staining modality for real-time inspection of dynamic phenotypes in multiple histological stains, Published: May 4, 2023,  – Read article here as PDF

Chao Han, Pengxuan Ren, Medina Mamtimin ,Linus Kruk, Edita Sarukhanyan , Chenyu Li, Hans-Joachim Anders , Thomas Dandekar  , Irena Krüger  , Margitta Elvers , Silvia Goebel ,Kristin Adler , Götz Münch  , Thomas Gudermann , Attila Braun and Elmina Mammadova-Bach. Minimal Collagen-Binding Epitope of Glycoprotein VI in Human and Mouse Platelets,  biomedicines 2023, 11/(2), 423Read article here as PDF


Contursi A, Ballerini P, Alberti S, Münch G, Patrignani P. The Novel Antiplatelet Agent Revacept in Cardiovascular Medicine: The Promise of Efficacy Without Bleeding. J Clin Cardiol. 2022;3(1):12-20.  – Read article here as PDF

Zhongmin Li, Goetz Muench, Clara Wenhart, Silvia Goebel & Andreas Reimann. Definition of a sectioning plane and place for a section containing hoped-for regions using a spare counterpart specimen. Nature/Scientifc Reports 12, Article number: 13342 (2022) – Read article here as PDF

Uphaus T; Richards T; Weimar C; Neugebauer H; Poli S; Weissenborn K; Imray  C; Michalski D; Rashid H; Loftus I; Rummey C; Ritter M; Hauser T-K; Münch G; Gröschel K; Poppert H.  Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial, Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.037006 Read article here as PDF


Mayer K, Hein-Rothweiler R, Schüpke S, et al. for the ISAR-Plaster investigators Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease The randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial –  Read article here as PDF

Supplemental Online Content – Mayer K, Hein-Rothweiler R, Schüpke S, et al. Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein vi, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. JAMA Cardiol. Published online March 31, 2021. doi:10.1001/jamacardio.2021.0475 Read article here as PDF

Zhongmin Li, Martin Ungerer, Julia Faßbender, Clara Wenhart, Hans-Peter Holthoff, Goetz Muench. Tissue block staining and domestic adhesive tape yield qualified integral sections of adult mouse orbits and eyeballs. PLOS ONE Read article online or Read article here as PDF

Clara Wenhart, Hans‑Peter Holthof, Andreas Reimann, Li Zhongmin, Julia Faßbender, Martin Ungerer – A fructosylated peptide derived from a collagen II T cell epitope for long‑term treatment of arthritis (FIA‑CIA) in mice. Nature/Scientifc Reports 2021 11:17345 Read article online or Read article here as PDF


Gröschel K, Uphaus T, Loftus I., Poppert H, Diener HC, Zobel J, Münch G. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. Volume 04, Number 04 of TH Open – Read article online oder Read article here as PDF

Hans-Peter Holthoff, Kerstin Uhland, Gabor Laszlo Kovacs, Andreas Reimann, Kristin Adler, Clara Wenhart and Martin Ungerer. Thyroid-stimulating hormone receptor (TSHR) fusion proteins in Graves’ disease. Journal of Endocrinology (2020) 246, 135–147 Read article online or Read article here as PDF

Sara Alberti, Qianqian Zhang, Ilaria D’Agostino, Annalisa Bruno, StefaniaTacconelli, Annalisa Contursi, Simone Guarnieri , Melania Dovizio, Lorenza Falcone , Patrizia Ballerini, Götz Münch , YingYu & Paola Patrignani. The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia. Nature Research Scientifc Reports Read article online oder Read article here as PDF


Zeibig S, Büttcher M, Goebel S,  Pauli J, Hunger A, Ungerer M, Gawaz M  Münch G. The Scavenger Receptor CD68 Regulates Platelet Mediated Oxidized Low-Density Lipoprotein (oxLDL) Deposition in Atherosclerotic Vessels at an Early Stage of Atherosclerosis in LDLR-/-/ApoBec-/- Mice. Cell Physiol Biochem 2019;52;681-695 – Read article online or Read article here as PDF

Faßbender J, Holthoff HP, Li Z, Ungerer M.  Therapeutic Effects of Short Cyclic and Combined Epitope Peptides in a Long-Term Model of Graves’ Disease and Orbitopathy. THYROID Volume 29, Number 2, 2019 – Read article here as PDF


Boivin-Jahns V, Uhland K, Holthoff H-P,Beyersdorf N, Kocoski V, Kerkau T, Münch G, Lohse M. Ungerer M, Jahns R. Cyclopeptide COR-1 to treat beta1-adrenergicreceptor antibody-induced heart failure. PLoS ONE13(8): publ Aug 20, 2018 – Read article here as PDF


Holthoff HP, Li Z, Faßbender J, Reimann Adler K, Münch G, Ungerer M, Cyclic Peptides for effective treatment in a long term model of Graves Disease and Orbitopathie in female mice , Endocrinology 158:1-16, 2017 – Read article here as PDF

Mojica Muñoz AK, Jamasbi J, Uhland K, Degen H, Münch G, Ungerer M, Megens R, Weber C, Lorenz R, Brandl R, Siess W. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. Thromb Haemost. 2017; 117(8):1651-1659 – Read article online

Degen H, Borst O, Ziegler M, Mojica Munoz AK, Jamasbi J, Walker B, Göbel S, Fassbender J, Adler K, Brandl R, Münch G, Lorenz R, Siess W, Gawaz M, Ungerer M. ADPase CD 39 fused to glycoprotein VI boosts local anti-thrombotic effects at vascular lesions. J Am Heart Ass 2017, 6:e005991; as of July 27, 2017 – Read article online or Read article here as PDF


Ungerer M, Faßbender J, Li Z, Münch G, Holthoff HP.  Review of Mouse Models of Graves’ Disease and Orbitopathy—Novel Treatment by Induction of Tolerance. Clinic Rev Allerg Immunol /2016-016-8562-7 – Read article here as PDF

Baumgartner C,  Brandl J,  Münch G, , Ungerer M. Rabbit models to study atherosclerosis and its complications e Transgenic vascular protein expression in vivo  Progress in Biophysics and Molecular Biology 121 (2016) 131e141 – Read article online


Kleiman NS; Kolandaivelu K. Expanding the Roster : Developing New Inhibitors of Intravascular Thrombosis.  J Am Coll Cardiol 2015; 65 (22): 2416 – 2419 – Read article online

Jamasbi J, Megens RTA, Bianchini M, Münch G, Ungerer M, Faussner A, Sherman S, Walker A, Goyal P, Jung S, Brandl R, Weber C, Lorenz R, Elia N, Farndale J, Siess W. Differential inhibition of human atherosclerotic plaque- induced platelet activation by dimeric GPVI-Fc and anti-GPVI antibodies: functional and imaging studies. J Am Coll Cardiol 2015; 65 (22): 2404-2415 – Read article online

Holthoff HP, Goebel S,  Li Z, Faßbender J,Reimann A, Zeibig S, Lohse M, Münch G, Ungerer M. Prolonged TSH Receptor A Subunit Immunization of Female Mice Leads to a Long-Term Model of Graves’Disease, Tachycardia, and Cardiac Hypertrophy. Endocrinology, April 2015, 156(4):1577–1589 – Read article here as PDF


Ungerer M, Münch G. Novel antiplatelet drugs in clinical development. Thromb Haemost 2013; 110 – Read article online

Dovizio M, Maier TH, Alberti S, Di Francesco L, Marcantoni E, Münch G, John C, Suess B, Sgambato A, Steinhilber D, Patrignani P. Pharmacological Inhibition of Platelet-Tumor Cell Cross-Talk Prevents Platelet-Induced Overexpression of Cyclooxygenase-2 in HT29 Human Colon Carcinoma Cells. Mol Pharmacol 84:25–40, July 2013 – Read article here as PDF

Ungerer M, Li ZM, Baumgartner C, Göbel S, Vogelmann J, Holthoff HP, Bültmann A, Gawaz M, Münch G. The GPVI – Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLOS ONE 2013; 8(8):e71193 – Read article online

Göbel S, Li ZM, Vogelmann J, Holthoff HP, Degen H, Hermann DM, Gawaz M, Ungerer M, Münch G. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLOS ONE 2013, 8(7):e66960 – Read article online

2010 - 2012

Baumer Y, Leder C, Ziegler M, Schönberger T, Ochmann C, Perk A, Degen H, Schmid-Horch B, Elvers M, Münch G, Ungerer M, Schlosshauer B, Gawaz M. The recombinant bifunctional protein aCD133–GPVI promotes repair of the infarcted myocardium in mice. J Thromb Haemost 2012; 10: 1152–64 – Read article here as PDF

Bültmann A, Li Z, Wagner S, Peluso M, Schönberger T, Weis C, Konrad I, Stellos K, Massberg S, Nieswandt B, Gawaz M, Ungerer M, Münch G. Impact of glycoprotein VI and platelet adhesion on atherosclerosis–a possible role of fibronectin. J Mol Cell Cardiol 2010; 49(3):532-42 – Read article online

Zeibig S, Li Z, Wagner S, Holthoff HP, Ungerer M, Bültmann A, Uhland K, Vogelmann J, Simmet T, Gawaz M, Münch G. Effect of the oxLDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. Circulation Research 2011; 108:695-703 – Read article online

Ungerer M, Rosport K, Bültmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Münch G. The novel anti-platelet drug Revacept (dimeric GPVI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general haemostasis in humans. Circulation 2011; 123: 1891-1899. – Read article online

Bültmann A, Li Z, Wagner S, Gawaz M, Ungerer M, Langer H, May A, Münch G. Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis. Int J Cardiol 152_2011 pp. 382-385 – Read article here as PDF

Holthoff HP, Zeibig S, Jahns-Boivin V, Bauer J, Lohse M, Kääb S, Clauss S, Jahns R, Schlipp A, Münch G, Ungerer M. Detection of  Anti–β1-AR Autoantibodies in Heart Failure by a Cell-Based Competition ELISA. Circulation Research. 2012;111:675–684 – Read article online or Read article here as PDF